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AbstrAct
Aims To describe the prevalence of heart failure (HF) 
stages in elderly outpatients with risk factors for HF 
but without known HF, and characterise the clinical, 
biochemical and echocardiographic findings in each stage.
Background Early stages of HF are underdiagnosed; 
nevertheless, they are associated with an increased risk of 
hospitalisation and increased mortality. The prevalence of 
HF stages in elderly high-risk patients is unknown.
Methods A total of 400 patients were consecutively 
included: ≥60 years old, ≥1 risk factor for HF (diabetes, 
chronic kidney disease, cardiovascular disease, atrial 
fibrillation, hypertension), and without known or suspected 
HF. HF stages were defined as the following: stage A 
(risk factor for HF, normal echocardiography), stage B 
(abnormal echocardiography, without symptoms of HF) 
and stage C (abnormal echocardiography, symptoms of HF, 
clinical signs/increased plasma aminoterminal pro-B-type 
natriuretic peptide [NT-proBNP] concentrations).
Results After thorough examination 44.25% of patients 
were categorised as HF stage A, 37.5% were HF stage B 
and 18.25% HF stage C. Those with higher stages of HF 
were older (p<0.001) and more often had atrial fibrillation 
(p=0.006). The median plasma NT-proBNP concentrations 
(pg/mL) were 132.5 for HF stage A, 275.5 for HF stage 
B and 400.0 for HF stage C (p<0.001). Detectable 
plasma troponin-I was more frequent with abnormal 
echocardiography: HF stage A 9.7%, HF stage B 27.3% 
and HF stage C 30.1% (p<0.001). HF stage C reported 
higher score on the Minnesota Living with Heart Failure 
Questionnaire (p<0.001).
Conclusions In an elderly high-risk population without 
known or suspected HF, more than half were HF stage 
B or C. Higher stages of HF had increased plasma 
concentrations of NT-proBNP and troponin-I, besides a 
reduced quality of life. Focus on symptoms and signs of HF 
in this population are warranted.
IntRoduCtIon
A large proportion of elderly people have 
early stages of heart failure (HF) based on 
the American College of Cardiology and 
the American Heart Association definition 
of HF stages.1 Increasing age of the general 
population and increasing prevalence of risk 
conditions (eg, hypertension, diabetes) lead 
to an increased number of persons with a 
risk of HF, categorised as HF stage A.2 3 Overt 
HF, categorised as HF stage C or D, is associ-
ated with poor prognosis, but also preclinical 
stages of HF, HF stage B, has an increased 
risk of hospitalisation with congestion and an 
increased mortality risk.4–7 Early recognition 
and improved treatment of risk conditions 
may delay the progression of early stages of 
HF.8 Furthermore, promising research in 
Key questions
What is already known about this subject?
 ► The heart failure (HF) staging definition introduced 
by the American College of Cardiology and the 
American Heart Association underlines the impor-
tance of recognition of asymptomatic patients with 
early stages of HF.
 ► Previous population-based studies have demon-
strated a high prevalence of early stages of HF, HF 
stages A and B, with an increased risk of hospital-
isation with HF and increased mortality.
What does this study add?
 ► In an elderly cohort living with risk factors for HF 
without known or suspected HF, more than half of 
the patients had an abnormal echocardiography and 
one-fifth had undiagnosed HF.
 ► The most common type of HF in this cohort was HF 
with preserved ejection fraction (HFpEF).
 ► Our findings suggest that increased focus on HF 
symptoms and thorough examination of high-risk 
patients can identify undiagnosed HF, in particular 
patients with HFpEF.
 ► This should be considered in specialised outpatient 
clinics treating the risk factors for HF and at the de-
partment of cardiology.
How might this impact on clinical practice?
 ► Our results underscore the need for increased focus 
on HF symptoms in high-risk populations to improve 
management of early stages of HF and improve pa-
tients’ quality of life, besides allocating patients with 
HFpEF to high-quality randomised clinical trials.
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box 1 Inclusion and exclusion criteria for the Copenhagen 
Heart Failure Risk Study
Inclusion criteria.
 ► Age ≥60 years.
 ► Plus, one or more risk factor for heart failure (HF).
 – Stable ischaemic heart disease.
 – Peripheral arterial disease.
 – Hypertension.
 – History of atrial fibrillation/atrial flutter, diabetes.
 – Apoplexia cerebri.
 – Chronic kidney disease.
Exclusion criteria.
 ► Age <60 years.
 ► No risk factor of HF.
 ► Previously diagnosed with or admitted for HF, known left ventricle 
ejection fraction ≤45%.
 ► Current admission with congestion or dyspnoea and suspected HF 
by the treating clinician.
 ► Advanced cardiac disease.
 – Moderate-severe valvular disease, third-degree atrioventricular 
block, pacemaker with >70% ventricular pace.
 ► Ongoing or recent cardiac disease or procedure.
 – Cardioversion within the previous 30 days, coronary angiography 
or percutaneous coronary intervention or coronary artery bypass 
operation within the previous 30 days, ongoing endocarditis or 
myocarditis, or pulmonary embolism.
 ► Dialysis/estimated glomerular filtration rate <15 mL/min/1.73 m2.
 ► Moderate-severe chronic obstructive pulmonary disease (global 
initiative for chronic obstructive lung disease stadium (GOLD) ≥2C).
 ► Sepsis (systemic inflammatory response system criteria) within the 
previous 30 days or ongoing intravenous antibiotic.
 ► Estimated survival less than 1 year (eg, terminal cancer or due to 
frailty).
the treatment of HF with preserved ejection fraction 
(HFpEF) is ongoing, and recognition of these patients 
needs to be improved to secure an optimal treatment.
Large community studies have observed that a consider-
able number of patients have early stages of HF. HF stage 
B was observed in 24%–34% and HF stage C in 12%–13% 
of these populations, with increasing prevalence with 
increasing age.4–6 The prevalence of HF stages B and C 
may, therefore, be even higher if a high-risk population is 
investigated, for example, elderly patients living with risk 
factors for HF.
The aim of this study was to evaluate the prevalence 
and clinical characteristics of HF stages in elderly patients 
with a high risk of HF, but without known or suspected 
HF.
MEtHods
study population
The Copenhagen Heart Failure Risk Study is a prospec-
tive cohort study. Patients were included from the 
Department of Cardiology, the Clinic of Diabetes and the 
Clinic of Nephrology at the Herlev and Gentofte Univer-
sity Hospital, Copenhagen, Denmark, enrolled from 
December 2014 to June 2016. Patients were screened 
consecutively during admission at the Department of 
Cardiology (screening 5 days a week), included from 
the day of discharge until 6 months later. Patients from 
the Clinic of Diabetes were screened consecutively by a 
treating physician at a scheduled visit (screening 2 days a 
week), included within 6 months. Patients from the Clinic 
of Nephrology were screened consecutively from the list 
of scheduled visits (screening 2 days a week), included 
within 6 months.
Inclusion and exclusion criteria are presented in 
Box 1. Data were collected during a single visit. Physical 
examination, medical history including current symp-
toms and medication, height, weight, non-invasive blood 
pressure, and 12-lead ECG were obtained; venous blood 
samples and spot-urinary sample were collected; patients 
fulfilled the Minnesota Living with Heart Failure Ques-
tionnaire (MLHFQ); and advanced echocardiography 
was performed. The Framingham probability of conges-
tive HF within 4 years score was calculated. This is a risk 
prediction model that includes age, systolic blood pres-
sure, heart rate, left ventricle (LV) hypertrophy on ECG, 
coronary heart disease, valve disease, diabetes and body 
mass index (if female).9
In total 3359 patients were screened and 400 patients 
were enrolled; inclusion flow is shown in figure 1. The 
primary reason for patients not being eligible for this 
study was due to the presence of one or more exclu-
sion criteria; especially patients from the Department of 
Cardiology often had advanced/ongoing cardiological 
diseases. No patients were excluded after inclusion, a 
full echocardiography was missing in one patient (n=1), 
and plasma concentrations of aminoterminal pro-B-type 
natriuretic peptide (NT-proBNP) was missing in one 
patient (n=1).
Echocardiography
Echocardiography was performed according to current 
guidelines.10 11 Examinations were performed on Vivid 
E9 (General Electric Vingmed Ultrasound, Horten, 
Norway) by the same trained physician. Analyses were 
made off-line in EchoPAC (V.201,70.1, General Elec-
tric Vingmed Ultrasound) by one physician, blinded to 
clinical and biochemical outcomes. Before examination 
patients were registered by name and social security 
number, height and weight were entered, and a three-
lead ECG of good quality was continually registered. In 
patients with sinus rhythm, three loops were recorded, 
and for atrial fibrillation (AF) five loops were recorded. 
Images for strain should have a frame rate of 40–80 
frames/s, while images for tissue Doppler >160 frames/s.
We predefined a study definition of an ‘abnormal echo-
cardiography’ based on current recommendations and 
previous studies in the elderly patients (online supple-
mentary table 1). Abnormal structure of the LV was 
defined as LV end-diastolic volume (LVEDV) indexed to 
body surface area (BSA) (female: >61 mL/m2, male: >74 
 o
n
 3 July 2019 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000840 on 27 February 2019. Downloaded from
 
3Gaborit FS, et al. Open Heart 2019;6:e000840. doi:10.1136/openhrt-2018-000840
Heart failure and cardiomyopathies
Figure 1 Inclusion flow of the Copenhagen Heart Failure 
Risk Study.
Figure 2 Prevalence of heart failure (HF) stages after 
clinical, biochemical and echocardiographic examination.
mL/m2)10 and LV mass indexed to BSA (female: >96 g/
m2, male: >116 g/m2).10 Abnormal systolic function was 
evaluated with left ventricle ejection fraction (LVEF) and 
global longitudinal strain (GLS). The limit for LVEF was 
set to detect mildly abnormal changes (female: ≤53%, 
male: ≤51%). The ARIC study has recently evaluated GLS 
in the HF staging system and confirmed its prognostic 
value for new-onset HF and mortality.4 However, vali-
dated reference limits do not exist, and therefore we used 
age-based and sex-based reference limits from the Fram-
ingham Heart Study12 (female: ≥−15.3%, male: ≥−14.7%). 
We included abnormal diastolic measures (tissue Doppler 
imaging and left atrial volume index), since these 
parameters have been associated to an increased risk of 
new-onset HF and mortality.4 5 The myocardial peak early 
velocity (e’) is more affected by ageing, and we adjusted 
the study reference value according to normal values 
reported from the Atherosclerosis Risk in Communities 
Study (ARIC)4 (female: <4.1 cm/s, male <4.3 cm/s), 
while standard reference values were used for the more 
robust E/e’ (lateral: >13, septal: >15) and for the left 
atrial volume indexed to BSA (≥35 mL/m2).11 Significant 
valvular disease was defined as moderate-severe aortic 
stenosis (aortic valve area <1 cm2), moderate-severe 
aortic regurgitation (visual judgement) and severe mitral 
stenosis (peak gradient mean >12 mm Hg).
LVEF (%) was calculated by the Simpson biplane 
method. Regional Wall Motion Score Index was calcu-
lated using the 16-segment model. LVEDV (mL) was 
calculated from apical two-chamber and four-chamber 
views. LV mass index (g/m2) was calculated from linear 
dimensions in the parasternal view. Left atrial end-systolic 
volume (mL) was calculated from apical two-chamber 
and four-chamber views. Myocardial peak early velocity 
(e’) (cm/s) and peak systolic velocity (s’) (cm/s) were 
measured medially and septally at the mitral annulus with 
pulse wave tissue Doppler. Mitral inflow was measured 
with pulse wave Doppler, peak velocity of early filling (E) 
(cm/s) and atrial filling (A) (cm/s), and mitral valve 
deceleration time (ms). E/e’ ratio was calculated septally 
and laterally. Tricuspid annular plane systolic excursion 
(mm) was measured with m-mode in the lateral tricuspid 
annulus. Longitudinal strain (%) was measured in three 
apical views, and GLS was calculated as the average of the 
three, an 18-segment model. The presence of valvular 
heart disease was evaluated: aortic sclerosis by visual 
judgement, aortic stenosis calculated (aortic velocity time 
integral [VTI], LV outflow tract VTI and diameter), aortic 
regurgitation by visual judgement of colour flow, mitral 
stenosis calculated (mitral valve VTI mean gradient), and 
mitral regurgitation by visual judgement of colour flow.
definition of HF stages
HF stages were defined according to the American 
College of Cardiology/American Heart Association defi-
nition1:
 ► HF stage A: patients with risk factors of HF, with 
normal echocardiography and without signs or symp-
toms of HF.
 ► HF stage B: patients with risk factors of HF, with an 
abnormal echocardiography but without past or 
current symptoms of HF.
 ► HF stage C: patients with an abnormal echocardiog-
raphy and past or current symptoms of HF.
To ensure the HF diagnoses in patients categorised as 
HF stage C, we used the European Society of Cardiology 
definition of HF.14 Signs of HF may be absent, for which 
reason a biochemical confirmation of HF was included. 
Patients in HF stage C needed to fulfil three criteria: 
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(1) symptoms of HF (two of the following: dyspnoea 
or orthopnoea and oedema, or treatment with loop 
diuretics); (2) abnormal echocardiography according to 
study definition; and (3) clinical signs and/or abnormal 
plasma concentrations of NT-proBNP (sinus rhythm >125 
ng/L,14 AF >524 pg/mL15).
Biochemistry
Venous blood samples were drawn on the day of exami-
nation. Routine blood samples (eg, haemoglobin, creati-
nine, highly sensitive C reactive peptide [hsCRP]) and 
urine-albumin were analysed successively. Blood samples 
for later tests were centrifuged at 4°, and plasma was stored 
at −80°C. Plasma concentrations of NT-proBNP (ng/L) 
were measured with the IMMULITE 2000 NT-proBNP, 
solid-phase, two-site chemiluminescent immunometric 
assay (Siemens Healthcare Diagnostics).16 Plasma 
concentrations of mid-regional proadrenomedullin 
(MR-proADM) (nmol/L) and copeptin (C-terminal 
provasopressin) (pmol/L) were measured on BRAHMS 
KRYPTOR with specified automated immunofluores-
cent assays.17 18 Plasma concentrations of troponin-I were 
measured with ADVIA Centaur TnI-Ultra assay (Siemens 
Healthcare Diagnostics).19 Concentrations of urinary 
albumin were measured in spot-urine. Microalbuminuria 
was defined as 20–199 mg/L and macroalbuminuria 
≥200 mg/L.
statistical methods
Patients were categorised in HF stages A, B and C. 
Dichotomous variables were presented as numbers 
and prevalences (%). Continuous variables were both 
normally and skewed distributed and are presented as 
medians with IQRs (25th and 75th percentiles). Base-
line characteristics and echocardiographic parameters 
were compared across HF stages, with pairwise compar-
isons between groups. For continuous variables, we used 
Wilcoxon rank-sum test (Kruskal-Wallis test) and a trend 
test, and for dichotomous variables we used χ2 test. In 
the pairwise comparison, we adjusted for multiple testing 
with the Bonferroni correction. Skewed distributed vari-
ables were log2-transformed when appropriate to reduce 
the effects of skewness. Trend tests were performed 
using the Cochran-Armitage trend test for proportions 
and logistic regression models for continuous variables 
(dependent variable: HF stages). Multivariate linear 
and logistic regression models were performed to eval-
uate the associations between the HF stages and baseline 
characteristic with a p value <0.05 in the trend test. The 
regression models were adjusted for age, gender, AF, 
hypertension, ischaemic heart disease, stroke, diabetes, 
estimated glomerular filtration rate (eGFR) and depart-
ment from where the patients were included. A two-sided 
p value <0.05 was considered significant, and in case of 
Bonferroni correction due to multiple testing a p value 
<0.05/3 (=0.017) was considered significant. Analyses 
were performed using the SAS Enterprise Guide V.7.11 
statistical software.
sample size
It was anticipated that the prevalence of patients with HF 
stage B or C would be 30%. With a power of 80% at a 
significance level of 5%, a total of 369 patients should be 
included. To account for dropouts and eventually missing 
data, 400 patients were included.
REsults
Prevalence of HF stages
Before examination by default, all patients were consid-
ered as HF stage A, based on the inclusion and exclusion 
criteria. After examination 177 (44.25%) remained as HF 
stage A, 150 (37.5%) were HF stage B and 73 (18.25%) 
were HF stage C, illustrated in figure 2. In HF stage A, 
29.9% reported symptoms of HF, 36.7% had clinical signs 
of HF and 50.6% had elevated plasma concentrations 
of NT-proBNP. However, these patients did not fulfil all 
the criteria for an HF diagnosis, and their symptoms may 
therefore be considered non-cardiac. Only 28.25% in 
HF stage A had no symptoms of HF, no clinical signs and 
normal plasma concentrations of NT-proBNP. In HF stage 
B, all patients had an abnormal echocardiography, 38.0% 
had clinical signs of HF and 73.3% had elevated plasma 
concentrations of NT-proBNP, and 30.7% had both clin-
ical signs of HF and elevated plasma concentrations of 
NT-proBNP. Two patients did not fit with the definition of 
HF stages; they had an abnormal echocardiography and 
symptoms of HF, but no clinical signs nor elevated plasma 
concentrations of NT-proBNP. They were categorised as 
HF stage B. Patients in HF stage C had an abnormal echo-
cardiography and symptoms of HF; 78.1% had clinical 
signs of HF and 83.6% had elevated plasma concentra-
tions of NT-proBNP, and 61.6% had both clinical signs of 
HF and elevated plasma concentrations of NT-proBNP.
Characterisation of HF stages
Baseline characteristics are presented in table 1. The 
median age was 72 years, ranging from 60 to 97, and 
patients in HF stage B and C were older than patients in 
HF stage A (p<0.001 for trend). Of the patients, 48.5% 
were female, with no significant difference between 
stages of HF.
Patients with HF stage C were more frequently admitted 
due to dyspnoea or palpitations. However, in all stages of 
HF, chest pain was the dominating reason for hospitalisa-
tion, and it did not differ between the different stages. 
The frequencies of chest pain and palpitations were 
almost identical to the frequencies of ischaemic heart 
disease and AF (table 1).
There was no difference in ‘numbers of risk factors’ 
(p=0.093 for trend); overall 119 patients had one risk 
factor, 184 had two risk factors, 79 had three risk factors 
and 18 had more than four risk factors. The only risk 
factor that differed in prevalence was a history of AF, 
with more patients in higher stages of HF (p=0.001 for 
trend). Patients with higher stages of HF had lower eGFR 
(p=0.003 for trend), haemoglobin (p=0.015 for trend) 
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Table 1 Clinical characteristics of patients in the Copenhagen Heart Failure Risk Study, according to HF stage
All patients
(n=400)
HF stage A
(n=177)
HF stage B
(n=150)
HF stage C
(n=73)
P value for 
trend
Age, years 72 (67, 78) 69 (65, 73)*† 75 (69, 79) 74 (69, 82) <0.001
Female sex, n (%) 194 (48.5) 78 (44.1) 74 (49.3) 42 (57.5) 0.053
BMI, kg/m2 27.3 (24.5, 30.9) 27.1 (24.3, 30.7) 27.2 (24.5, 30.1) 28.3 (24.7, 32.8) 0.117
BMI ≥30, n (%) 119 (29.8) 52 (29.4) 39 (26.0) 28 (38.4) 0.309
Systolic blood pressure, mm Hg 137.0 (126.5, 149.0) 134.0 (126.0, 146.0) 140.0 (128.0, 150.0) 137 (125.0, 150.0) 0.312
Diastolic blood pressure, mm Hg 79.0 (72.0, 85.0) 81.0 (74.0, 85.0)† 78.0 (71.0, 86.0) 77.0 (69.0, 84.0) 0.0135
HR, beats/min 69.0 (60.0, 79.0) 69.0 (61.0, 78.0) 68.5 (60.0, 81.0) 69.0 (60.0, 79.0) 0.471
Left branch bundle block ECG, n (%) 13 (3.3) 1 (0.6)*† 8 (5.3) 4 (5.6) 0.015
Right branch bundle block ECG, n (%) 25 (6.3) 11 (6.2) 7 (4.7) 7 (9.7) 0.475
LV hypertrophy ECG, n (%) 7 (1.8) 2 (1.1) 4 (2.7) 1 (1.4) 0.675
NYHA class I, n (%) 235 (58.8) 117 (66.1)† 98 (65.3)‡ 20 (27.4) <0.001
NYHA class II, n (%) 145 (36.3) 55 (31.1)† 45 (30.0)‡ 45 (61.6) <0.001
NYHA class III, n (%) 20 (5.0) 5 (2.8)† 7 (4.7) 8 (11.0) 0.012
Smoking (former or active), n (%) 249 (62.3) 120 (67.8)* 81 (54.0) 48 (65.8) 0.316
Variables for HF staging 
  Symptoms of heart failure, n (%) 128 (32.0) 53 (29.9)*† 2 (1.3)‡ 73 (100)
  Clinical signs of heart failure, n (%) 179 (44.8) 65 (36.7)† 57 (38.0)‡ 57 (78.1)
  Abnormal echocardiography, n (%) 223 (55.8) 0 (0.0)*† 150 (100) 73 (100)
  MLHFQ 12.0 (2.0, 28.0) 11.0 (2.0, 28.0)† 8.0 (1.0, 17.0)‡ 25.0 (16.0, 42.0) 0.001
  Framingham 4-year HF risk score 11.0 (8.0, 15.0) 9.0 (7.5, 14.0)*† 11.5 (9.0, 16.0) 12.0 (9.0, 16.0) <0.001
  Indication for hospitalisation 0.043
  Chest pain, n (%) 115 (28.8) 55 (31.1) 38 (25.3) 22 (30.1) 0.646
  Palpitations/Arrhythmia, n (%) 80 (20.0) 25 (14.1) 36 (24.0) 19 (26.0) 0.013
  Syncope, n (%) 30 (7.5) 11 (6.2) 13 (8.7) 6 (8.2) 0.477
  Dyspnoea, n (%) 12 (3.0) 4 (2.3) 2 (1.3) 6 (8.2) 0.044
  Other, n (%) 9 (2.3) 4 (2.3) 5 (3.3) 0 (0) 0.545
  Ambulatory visits—Clinic of Diabetes, 
n (%)
78 (19.5) 40 (22.6) 28 (18.7) 10 (13.7) 0.100
  Ambulatory visits—Clinic of Nephrology, 
n (%)
76 (19.0) 38 (21.5) 28 (18.7) 10 (13.7) 0.160
Medical history 
  Hypertension, n (%) 328 (82.0) 145 (81.9) 120 (80.0) 63 (86.3) .568
  Ischaemic heart disease, n (%) 98 (24.5) 37 (20.9) 41 (27.3) 20 (27.4) 0.187
  Atrial fibrillation, n (%) 119 (29.8) 40 (22.6)† 48 (32.0) 31 (42.5) 0.001
  Diabetes, n (%) 143 (35.8) 69 (39.0) 51 (34.0) 23 (31.5) 0.218
  Chronic kidney disease, n (%) 63 (15.8) 30 (17.0) 23 (15.3) 10 (13.7) 0.506
  Apoplexia cerebri, n (%) 48 (12.0) 19 (10.7) 23 (15.3) 6 (8.2) 0.915
  Mild COPD or asthma, n (%) 34 (8.5) 18 (10.2) 6 (4.0)‡ 10 (13.7) 0.840
Evaluation of risk factors
  Risk factors, n (%) 2.0 (1.0, 2.0) 2.0 (1.0, 2.0) 2.0 (1.0, 3.0) 2.0 (2.0, 2.0) 0.093
  More than two risk factors, n (%) 97 (24.3) 39 (22.0) 41 (27.3) 17 (23.3) 0.615
Medication
  ACE inhibitor, n (%) 105 (26.3) 49 (27.7) 45 (30.0)‡ 11 (15.1) 0.103
  Angiotensin receptor antagonist, n (%) 139 (34.8) 59 (33.3) 51 (34.0) 29 (39.7) 0.388
  Aldosterone antagonist, n (%) 5 (1.3) 0 (0.0) 3 (2.0) 2 (2.7) 0.047
  Calcium antagonist, n (%) 125 (31.3) 48 (27.1) 50 (33.3) 27 (37.0) 0.097
Continued
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All patients
(n=400)
HF stage A
(n=177)
HF stage B
(n=150)
HF stage C
(n=73)
P value for 
trend
  Beta blocker, n (%) 187 (46.8) 71 (40.1) 75 (50.0) 41 (56.2) 0.012
  Loop diuretics, n (%) 60 (15.0) 16 (9.0)* 15 (10.0)‡ 29 (39.7) <0.001
  Thiazide, n (%) 125 (31.3) 62 (35.0)† 49 (32.7) 14 (19.2) 0.025
  Statin, n (%) 247 (61.8) 115 (65.0) 90 (60.0) 42 (57.5) 0.226
  Per oral antidiabetics, n (%) 111 (27.8) 57 (32.2) 35 (23.3) 19 (26.0) 0.172
  Insulin, n (%) 65 (16.3) 34 (19.2) 22 (14.7) 9 (12.3) 0.141
Biochemistry
  Haemoglobin, g/L 138.6 (128.9, 146.6) 140.2 (132.1, 148.2)† 137.0 (125.7, 146.6) 133.7 (127.3, 145.0) 0.015
  Thrombocytes, ×109/L 232.2 (190.5, 280.0) 230.0 (193.0, 281.0) 228.5 (189.0, 270.0) 242.0 (184.0, 286.0) 0.960
  Leucocytes, ×109/L 7.2 (6.1, 8.4) 7.2 (6.1, 8.4) 7.0 (5.9, 8.1)‡ 7.5 (6.6, 8.5) 0.092
  hsCRP, mg/L 0 (0.0, 3.0) 0 (0.0, 3.0) 0 (0.0, 4.0) 0 (0.0, 4.0) 0.621
  hsCRP ≥3 mg/L, % 130 (32.5) 48 (27.1) 55 (36.7) 27 (37.0) 0.067
  Creatinine, µmol/L 82.0 (69.0, 106.0) 80.0 (66.0, 103.0) 82.0 (71.0, 109.0) 87.0 (68.0, 116.0) 0.213
  eGFR, mL/min/1.73 m2 70.0 (53.0, 86.0) 76.0 (57.5, 90.0)*† 65.5 (51.0, 84.0) 65.0 (47.5, 83.5) 0.003
  Microalbuminuria, % 143 (37.9) 51 (31.1) 61 (43.3) 31 (43.1) 0.036
  Macroalbuminuria, % 38 (10.1) 13 (7.9)* 18 (12.8) 7 (9.7) 0.457
  HbA1c, % 5.8 (5.5, 6.6) 5.8 (5.6, 6.9) 5.8 (5.5, 6.5) 5.8 (5.6, 6.4) 0.186
  Albumin, g/L 42.0 (40.0, 44.0) 43.0 (40.0, 45.0)*† 42.0 (40.0, 44.0) 41.0 (40.0, 44.0) <0.001
  Bilirubin, µmol/L 10.0 (8.0, 14.0) 10.0 (7.0, 14.0) 11.0 (8.0, 14.0) 10.0 (8.0, 14.5) 0.037
  ALAT, U/L 29.0 (22.0, 39.0) 31.0 (24.0, 39.0) 27.0 (20.0, 40.0) 26.0 (20.0, 37.0) 0.524
  TSH, ×10−3 IE/L 1.3 (0.8, 1.9) 1.3 (0.8, 1.8) 1.2 (0.8, 1.8) 1.6 (0.9, 2.4) 0.109
  Cholesterol total, mmol/L 4.4 (3.7, 5.2) 4.5 (3.7, 5.3) 4.3 (3.7, 5.2) 4.3 (3.6, 5.1) 0.332
  HDL, mmol/L 1.2 (1.0, 1.6) 1.3 (1.0, 1.5) 1.2 (1.0, 1.6) 1.3 (1.0, 1.6) 0.508
  LDL, mmol/L 2.2 (1.6, 2.9) 2.2 (1.7, 2.9) 2.2 (1.7, 2.8) 2.2 (1.6, 2.7) 0.521
  NT-proBNP, ng/L 203.0 (98.0, 601.0) 132.5 (70.0, 320.0)*† 275.5 (118.0, 746.0) 400.0 (179.0, 1210.0) <0.001
  Troponin-I, ng/L 0 (0.0, 0.0) 0 (0.0, 0.0) 0 (0.0, 12.0) 0 (0.0, 12.0) 0.490
  Troponin-I ≥10, ng/L, % 80 (20.1) 17 (9.7) 41 (27.3) 22 (30.1) <0.001
  MR-proADM, nmol/L 0.85 (0.66, 1.06) 0.75 (0.59, 0.95)*† 0.87 (0.69, 1.07)‡ 1.00 (0.84, 1.17) <0.001
  Copeptin, pmol/L 7.2 (4.5, 14.3) 6.4 (3.8, 12.5) 7.6 (4.9, 14.5) 9.3 (5.2, 19.7) 0.013
Categorical values are presented in percentages, and continuous values are presented as median with 25th and 75th percentile.
*P<0.017 for HF stage A vs HF stage B.
†P<0.017 for HF stage A vs HF stage C.
‡P<0.017 for HF stage B vs HF stage C.
ALAT, alanine transaminase; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration 
rate; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; HF, heart failure; HR, heart rate; hsCRP, highly sensitive C reactive peptide; 
LDL, low-density lipoprotein; LV, left ventricle; MLHFQ, Minnesota Living with Heart Failure Questionnaire; MR-proADM, mid-regional 
proadrenomedullin; NT-proBNP, aminoterminal pro-brain natriuretic peptide; NYHA, New York Heart Association; TSH, thyroid stimulating 
hormone.
Table 1 Continued
and plasma albumin (p<0.001 for trend) (table 1). In the 
adjusted analyses the associations between HF stages and 
age, diastolic blood pressure, MLHFQ, haemoglobin, 
eGFR, prevalence of microalbuminuria and bilirubin 
remained significant (table 2).
Plasma concentrations of NT-proBNP increased with 
higher stages of HF (p<0.001), with a significant difference 
between each stage, illustrated in figure 3. Plasma concen-
trations of troponin-I were more frequently increased 
in patients with HF stages B and C (p<0.001 for trend). 
Plasma concentrations of copeptin and MR-proADM also 
increased with higher stages of HF (p<0.001 for trend). 
MLHFQ score was higher in patients with HF stage C, 
reflecting a decreased quality of life (p<0.001 for trend). 
Framingham probability of congestive HF within 4 years 
score was higher in patients with HF stages B and C (p<0.001 
for trend), illustrated in figure 3. In the adjusted analyses 
the associations between HF stages and increased plasma 
troponin-I concentrations (p=0.010), plasma NT-proBNP 
concentrations (p<0.001), plasma MR-proADM concen-
trations (p<0.001) and plasma copeptin concentrations 
(p=0.009) remained significant (table 2).
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Table 2 Multivariate regression models according to HF 
stages
Multivariate linear regression models according to HF 
stages
Estimate 95% CI P value
Age <0.001
  HF stage A Ref
  HF stage B 3.55 2.137 to 4.956 <0.001
  HF stage C 3.33 1.525 to 5.128 <0.001
Diastolic blood pressure <0.001
  HF stage A Ref
  HF stage B −0.09 −2.291 to 2.106 0.934
  HF stage C −1.87 −4.640 to 0.901 0.185
Minnesota Living 
with Heart Failure 
Questionnaire
0.049
  HF stage A Ref
  HF stage B −6.11 −10.32 to 1.89 0.005
  HF stage C 12.33 7.18 to 17.56 <0.001
Framingham 4-year risk 
of congestion
0.118
  HF stage A Ref
  HF stage B 0.36 −0.33 to 1.05 0.306
  HF stage C 0.61 −0.26 to 1.48 0.17
Haemoglobin <0.001
  HF stage A Ref
  HF stage B −0.06 −0.26 to 0.14 0.528
  HF stage C −0.15 −0.41 to 0.10 0.232
eGFR <0.001
  HF stage A Ref
  HF stage B −1.36 −5.25 to 2.54 0.495
  HF stage C −2.77 −7.67 to 2.14 0.269
Bilirubin <0.001
  HF stage A Ref
  HF stage B 1.04 −0.08 to 2.17 0.069
  HF stage C 1.1 −0.32 to 2.52 0.128
Albumin <0.001
  HF stage A Ref
  HF stage B −0.65 −1.39 to 0.09 0.084
  HF stage C −0.84 −1.76 to 0.09 0.077
NT-proBNP <0.001
  HF stage A Ref
  HF stage B 0.34 0.02 to 0.66 0.036
  HF stage C 0.87 0.48 to 1.28 <0.001
MR-proADM <0.001
  HF stage A Ref
  HF stage B 0.07 −0.03 to 0.17 0.179
  HF stage C 0.29 0.16 to 0.42 <0.001
Continued
Multivariate linear regression models according to HF 
stages
Estimate 95% CI P value
Copeptin 0.009
  HF stage A Ref
  HF stage B 0.16 −0.15 to 0.35 0.422
  HF stage C 0.16 0.11 to 0.74 0.008
Multivariate logistic regression models according to HF 
stages
OR 95% CI P value
Left branch bundle block on 
ECG
0.217
  HF stage A vs HF stage B 6.44 0.68 to 60.56 0.104
  HF stage A vs HF stage C 8.16 0.74 to 90.51 0.087
NYHA class 
  HF stage A vs HF stage B 1.21 0.74 to 1.99 0.446
  HF stage A vs HF stage C 0.29 0.16 to 0.52 <0.001
Atrial fibrillation <0.001
  HF stage A vs HF stage B 1.48 0.78 to 2.80 0.227
  HF stage A vs HF stage C 2.39 1.12 to 5.10 0.024
Microalbuminuria 0.008
  HF stage A vs HF stage B 1.35 0.82 to 2.25 0.241
  HF stage A vs HF stage C 1.3 0.69 to 2.44 0.412
Troponin-I ≥10 ng/L 0.01
  HF stage A vs HF stage B 2.35 1.21 to 4.54 0.011
  HF stage A vs HF stage C 2.55 1.18 to 5.50 0.017
The response variables are specified below. The predictor 
variables are HF stages, age, gender, atrial fibrillation, 
hypertension, ischaemic heart disease, stroke, diabetes, kidney 
function (eGFR) and department from where the patients are 
included.
HF, heart failure; MR-proADM, mid-regional proadrenomedullin; 
NT-proBNP, aminoterminal pro-brain natriuretic peptide; NYHA, 
New York Heart Association; Ref, reference; eGFR, estimated 
glomerular filtration rate.
Table 2 Continued
Echocardiographic parameters are presented in 
table 3. An ‘abnormal echocardiography’ was part of 
the HF stages B and C definition, and this reflects in 
the results with no major differences between the two. 
The only echocardiographic parameters with a differ-
ence between HF stages B and C were the proportion 
of abnormal LV mass index (p<0.001 for trend) and the 
proportion of abnormal e’ septal (p<0.0001 for trend). 
The median LVEF was 62.64%, slightly lower in higher 
stages of HF (p<0.0001). In total 12 patients (3%) had 
an LVEF ≤40%, of these 8 had no symptoms and were 
therefore HF stage B, while 4 reported symptoms of HF 
and were therefore HF stage C.
Despite having excluded patients with known moder-
ate-severe valvular heart disease, two patients were 
encountered with moderate-severe aortic stenosis (aortic 
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Figure 3 Cardiac biomarkers, quality of life and Framingham HF risk score according to HF stages. Plasma concentrations of 
NT-proBNP presented as median with 25th and 75th percentiles and patients with elevated troponin-I (≥10 ng/L) as proportion 
(%) according to HF stages. Minnesota Living with Heart Failure Questionnaire and Framingham probability of congestive HF 
within 4 years score presented as median with 25th and 75th percentiles. HF, heart failure; NT-proBNP, aminoterminal pro-brain 
natriuretic peptide.
valve area <1.0 cm2) and one with moderate-severe aortic 
regurgitation. No patients with severe mitral regurgita-
tion were encountered.
dIsCussIon
The main findings of this study were that HF stages B and 
C are frequent in an elderly high-risk population without 
known or suspected HF, and especially HFpEF is underdi-
agnosed. Clinical characteristics were similar in HF stages 
B and C; however, plasma concentrations of NT-proBNP 
increased with higher stages of HF, whereas troponin-I 
was more frequently detectable in patients with an 
abnormal echocardiography. Finally, higher stages of HF 
had decreased quality of life.
Clinical characteristics of HF stages
Elderly patients with one or more risk factor for HF often 
present with symptoms compatible with HF. After a thor-
ough examination, we observed that more than half of the 
patients had structural or functional abnormalities of the 
LV evaluated by echocardiography and almost one-fifth of 
the patients had undiagnosed HF. Previous studies have 
examined the distribution of HF stages in the community, 
but to our knowledge this is the first study to describe the 
prevalence of HF stages in elderly patients living with risk 
factors for HF, under relevant medical care. The findings 
of this study are in fine line with the prevalence of HF 
stages found in large community studies.4–6 However, by 
focusing on high-risk patients, we increased the observed 
prevalence of HF stages B and C. In the present study 
the patients in HF stage C were more likely to be older 
and have a history of AF, which was also the case for the 
patients in HF stage B. Despite symptoms of HF, no clin-
ical characteristics clearly distinguished HF stages. Other 
studies have found an increased prevalence of higher 
age, male gender, obesity, atrial fibrillation and diabetes 
with higher stages of HF.4 20 Thus, the lack of differences 
in clinical characteristics between HF stages underscores 
the importance of focusing on symptoms in daily clin-
ical practice in elderly patients with a risk factor for HF. 
Patients in HF stages A and B are considered patients at 
risk of overt HF. Previous studies have demonstrated an 
increased mortality risk and risk of admission for HF in 
patients in HF stage B.4–6 Further, it should be noticed 
that patients in HF stage B may have increased plasma 
concentrations of NT-proBNP and eventually signs of HF, 
but due to lack of symptoms these patients do not fulfil 
the criteria for overt HF (HF stage C).
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Echocardiographic characteristics of HF stages
Echocardiographic parameters were used to identify 
patients in both HF stages B and C. In this study compa-
rable prevalence of structural and functional abnormali-
ties of the myocardium was found in HF stages B and C, 
and only LV mass index and e’ septal differed between 
HF stages B and C. Other studies have observed a more 
pronounced difference in echocardiographic variables, 
increasingly so with higher stages of HF.4 20
An important finding of this study was the substantial 
number of patients with HF stage C (n=73), undiagnosed 
HF. Among patients with HF stage C, 80.6% had HFpEF 
(LVEF ≥50%), 13.7% had HF with mid-range LVEF 
(LVEF 41%–50%) and 5.5% had HF with reduced LVEF 
(LVEF ≤40%). Compared with other studies the echocar-
diographic findings in this study confirm the increased 
risk of HF these patients present, with E/e’ septal >15 in 
one-fifth of the patients21 and left atrial size ≥35 mL/m2 
in almost one-third of the patients.22 Finally, a total of 88 
patients (n=69 with sinus rhythm and n=19 with AF) had 
fulfilled the echocardiographic and NT-proBNP criteria 
for inclusion in the Paragon trial. However, the number 
was reduced to 27 when including the criteria of New 
York Heart Association (NYHA) class and treatment with 
a diuretic.23 Currently there is no established treatment 
for HFpEF; instead, focus on the treatment of comorbid-
ities, for example, hypertension and atrial fibrilation, is 
recommended. In patients with type 2 diabetes, treatment 
with a sodium glucose inhibitor should be considered.24 
Based on post-hoc analyses from the Irbesartan in Heart 
Failure With Preserved Systolic Function (I-PRESERVE) 
trial25 and the Treatment of Preserved Cardiac Function 
Heart Failure with an Aldosterone Antagonist (TOPCAT) 
trial,26 it may be speculated that HF stage C patients, with 
relatively low plasma concentrations of NT-proBNP, could 
benefit from treatment with an aldosterone antagonist.27
Cardiac biomarkers and HF stages
Plasma concentrations of NT-proBNP increased with 
higher stages of HF. These observations are supported 
by similar findings in community-based studies of HF 
stages.4 6 7 Elevated plasma concentrations of NT-proBNP 
are expected in HF stage C, but the elevated concentra-
tions in HF stage B suggest that already in this early stage 
of HF, in asymptomatic patients, the heart is subject to 
an increased wall stress. This study is the first to describe 
that plasma concentrations of copeptin increase with 
increasing stages of HF. Copeptin is a surrogate marker 
for vasopressin and reflects neurohumoural activation. It 
has prognostic value in both acute and chronic HF, and in 
elderly patients with symptoms of HF.28 We also observed 
increased plasma concentrations of MR-proADM with 
higher stages of HF, which also reflects increased neuro-
humoural activation in higher stages of HF. This finding 
has previously been observed in stable outpatients with 
HF.29
In this present study, an increased proportion of 
patients in both HF stages B and C had detectable 
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troponin-I, while other studies have found increasing 
plasma concentrations of troponin with each stage of 
HF.4 6 We found that only one-fifth of the patients had 
troponin-I above the detection limit, and from our obser-
vations elevated troponin-I is more coherent with an 
abnormal echocardiogram than with HF stages. Tropo-
nin-I has been associated with increased mortality risk.30
In contrast, higher stages of HF were not associated 
with increased plasma concentrations of hsCRP. Coro-
nary microvascular inflammation has been suggested as 
a driver in the development of HFpEF.31 Lack of systemic 
inflammation or the need for a more sensitive biomarker 
reflecting inflammation32 may be the reason.
Quality of life (MlHFQ) and Framingham risk score of HF
Symptoms of HF were part of the definition of HF stage 
C, and higher stages of HF more often presented with a 
higher NYHA class. Patients in HF stage C also presented 
with decreased quality of life compared with HF stages A 
and B, respectively; this aspect has not been described in 
other studies. The quality of life decreases with severity 
of overt HF,33 but it is noteworthy that also patients with 
undiagnosed HF stage C have a reduced quality of life.
In the present study Framingham 4-year risk score of 
congestive HF was increased in both HF stages B and C. 
However, the risk score was low, and the median prob-
ability for hospitalisation for congestion within 4 years 
was only increased by 3% for both men and women. 
Other studies have reported increased mortality rate with 
higher stages of HF, most pronounced for HF stages C 
and D.4 5 20 These numbers are hardly comparable since 
this study has no follow-up data; however, such a differ-
ence might occur due to different inclusion criteria.
Methodological considerations and perspectives
Some methodological considerations of this study should 
be addressed. Patients in this study were selected from 
three highly specialised sections at the hospital, according 
to predefined inclusion and exclusion criteria, with the 
purpose to evaluate whether HF was underdiagnosed in 
a high-risk population, with no current suspicion of HF 
by the treating clinician. Therefore, the findings in this 
cohort do not reflect the general population. Instead, as 
we intended, the study reflects the risk of HF in an elderly 
high-risk population.
The definition of abnormal echocardiographic param-
eters and the definition of HF in the present study need 
to be discussed. It may be argued that the definition of 
an abnormal echocardiography is too wide and that this 
has resulted in an overestimation of the prevalence of HF 
stages B and C. However, the definition was predefined 
before data analysis and inspired by current guidelines 
and previous studies. The ARIC study examined the 
effect of including diastolic measures in the definition 
of structural heart disease, and concluded that diastolic 
measures should be included4; similar results have been 
reported from Olmsted County.5 Further, the definition 
of overt HF (HF stage C) can also be discussed. We used 
the European Society of Cardiology’s definition and 
required that symptoms of both dyspnoea or orthop-
noea and oedema or use of loop diuretics were present. 
It was the intention to be conservative and avoid a type I 
error (‘false positive cases’). In contrast, it may be argued 
that we have made a type II error (‘false negative cases’) 
because 30% of the patients in HF stage B were evalu-
ated to be NYHA class II, but did not report symptoms 
themselves. A bicycle test with invasive measurement of 
filling pressures might have revealed reduced exercise 
capacity and increased filling pressures, thereby classi-
fying these patients as HF stage C.34 Functional class was 
evaluated by a single investigator, and a stress test, for 
example, 6 min walking test, was not conducted in cases 
of doubt. Misclassification of functional status may there-
fore be present, but it should be noted that NT-proBNP 
increased according to HF stages. Dyspnoea may also be 
explained by ageing, obesity, physical fitness, chronic 
obstructive pulmonary disease and AF. Finally, we did not 
evaluate the prevalence of HF in different subgroups due 
to the sample size, and our data therefore elucidate the 
prevalence of early stages of HF in an elderly high-risk 
population with different risk factors for HF.
ConClusIon
HF stages B and C are frequent in an elderly high-risk 
population without known or suspected HF, and espe-
cially HFpEF is underdiagnosed. Clinical characteristics 
are similar in early stages of HF, but the plasma concen-
trations of NT-proBNP are increasing with higher stages 
of HF, and troponin-I is more frequently detectable if the 
echocardiography is abnormal. Finally, higher stages of 
HF are associated with a decreased quality of life even in 
patients with undiagnosed HF.
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